BSYI Stock Overview

Develops biotherapeutic thermogels for tissue repair and therapeutic delivery. More details

BSYI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($1K)

Latest financial reports are more than a year old

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

BioSyntech, Inc. Competitors

Molecular Templates

OTCPK:MTEM

US$2.0k

Gritstone bio

OTCPK:GRTS.Q

US$147.0

DermTech

OTCPK:DMTK.Q

US$35.0

Vaxxinity

OTCPK:VAXX

US$633.7k

Price History & Performance

Summary of share price highs, lows and changes for BioSyntech
Historical stock prices
Current Share Price	US$0.00001
52 Week High	US$0.00001
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-99.79%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	BSYI	US Biotechs	US Market
7D	0%	1.7%	-0.9%
1Y	n/a	-2.2%	22.6%

Return vs Industry: Insufficient data to determine how BSYI performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how BSYI performed against the US Market.

Price Volatility

Is BSYI's price volatile compared to industry and market?
BSYI volatility
BSYI Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.3%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.7%
10% least volatile stocks in US Market	3.2%

Stable Share Price: BSYI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine BSYI's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1994	n/a	n/a	n/a

BioSyntech, Inc. develops biotherapeutic thermogels for tissue repair and therapeutic delivery. Its lead products in development include BST-CarGel, a biodegradable gel for cartilage repair; BST-InPod for heel pain relief; BST-DermOn for chronic wound healing; BST-Ossifil for bone filling; BST-Ossifix for bone structural support; and BST-Disc for intervertebral disc restoration. The company’s products also comprise BST-Gel-based injectable products that deliver biotherapeutics to their targeted site of action; Arthro-BST, an arthroscopic device used for the non-destructive evaluation of cartilage degradation and/or repair; and Mach-1, a micromechanical testing system for evaluating the mechanical properties of tissues and materials.

BioSyntech, Inc. Fundamentals Summary

How do BioSyntech's earnings and revenue compare to its market cap?
BSYI fundamental statistics
Market cap	US$1.16k
Earnings (TTM)	-US$8.85m
Revenue (TTM)	US$138.97k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is BSYI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BSYI income statement (TTM)
Revenue	CA$199.70k
Cost of Revenue	CA$69.36k
Gross Profit	CA$130.34k
Other Expenses	CA$12.85m
Earnings	-CA$12.72m

Last Reported Earnings

Dec 31, 2009

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did BSYI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 12:31
End of Day Share Price	2024/09/24 00:00
Earnings	2009/12/31
Annual Earnings	2009/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioSyntech, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution